Study Captures Ethnic Disparities in Pain Reporting
Using uMotif eCOA/ePRO data capture app, significant ethnic disparities in pain recognition and management are revealed.
Participants identifying as South Asian, Black African, and White British used a smartphone-based digital pain self-reporting app created by uMotif to provide feedback in a University of Manchester study, with results published in the report “Exploring the Cross-cultural Acceptability of Digital Tools for Pain Self-reporting: Qualitative Study.” https://humanfactors.jmir.org/2023/1/e42177
Professor Will Dixon, Chair in Digital Epidemiology at the University of Manchester, explained, “We are hopeful this study will lead to improvements in accurate and acceptable self-reporting of pain across cultures, so people of different ethnic groups can be assured of actively contributing to better future clinical care and research about their pain, regardless of their background.”
Participants used the app to report overall pain intensity on a scale from 0-10; location-specific pain intensity and a free text pain diary.
Four main themes emerged from the interpretive analysis: perceived causes of pain; approaches and attitudes to self-treatment and management; frustration and embarrassment in communicating about pain with others; and lack of experience with formal pain assessment tools. One result from the study found that people from non-White ethnic backgrounds had different beliefs and perceptions on pain compared to those from White backgrounds, which resulted in internalizing stigma and developing a negative attitude toward medication and pain reporting.
uMotif co-founder and chief design officer Ben James said, “Our research underscores the absolute necessity of putting the patient first when designing self-reporting apps. Making the effort to understand and meet the patient where they are will enable vast improvements in healthcare, and will open clinical research to a massive and diverse patient population.”
Reference:
University of Manchester Study Using uMotif Next-Generation eCOA/ePRO Data Capture App Reveals Significant Ethnic Disparities in Pain Recognition and Management. BOSTON MA and LONDON UK – May 31, 2023.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
